Colon specific delivery of indomethacin: Effect of incorporating pH sensitive polymers in xanthan gum matrix bases

AAPS PharmSciTech

Volumn 10, Issue 2, 2009, Pages 418-429

  Asghar, Laila F A ^a   Chure, Chetan B ^a   Chandran, Sajeev ^a,b  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^b LUPIN LIMITED   (India)

Author keywords

Colon specific delivery; Controlled release; Eudragits; Matrix; pH sensitive polymers; Xanthan gum

Indexed keywords

EUDRAGIT; INDOMETACIN; XANTHAN; BACTERIAL POLYSACCHARIDE; METHYLMETHACRYLATE METHACRYLIC ACID COPOLYMER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; POLYMETHACRYLIC ACID DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG COATING; DRUG ELIMINATION; DRUG SOLUBILITY; DRUG STABILITY; GASTROINTESTINAL TRACT; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PH; RAT; REPRODUCIBILITY; ANIMAL; CHEMISTRY; COLON; DELAYED RELEASE FORMULATION; MALE; METABOLISM; SOLUBILITY; TABLET; WISTAR RAT;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; COLON; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; INDOMETHACIN; MALE; POLYMETHACRYLIC ACIDS; POLYSACCHARIDES, BACTERIAL; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SOLUBILITY; TABLETS;

EID: 67549130675     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9223-4     Document Type: Article

References (56)

1. Hull MA, Gardner SH, Hawcroft G. Activity of the non-steroidal anti- inflammatory drug indomethacin against colorectal cancer. Cancer Treat Rev. 2003;29:309-20.
2. Mandayam S, Huang R, Tarnawski AS, Chiou SK. Roles of survivin isoforms in the chemopreventive actions of NSAIDS on colon cancer cells. Apoptosis. 2007;12:1109-16.
3. Kapitanovi S, Čačev T, Antica M, Kralj M, Cavrí G, Krešimir P, et al. Effect of indomethacin on E-cadherin and β-catenin expression in HT-29 colon cancer cells. Exp Mol Pathol. 2006;80:91-6.
4. Fujino H, Chen XB, Regan JW, Murayama T. Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells. Biochem Biophys Res Commun. 2007;359(3):568-73.
5. Goodman GA, Goodman LS. Analgesics-antipyretics; pharmacotherapy of gout. In: Brunton, editor. The pharmacological basis of therapeutics, 11th edn. New York: Mcgraw Hill; 2006. p. 699-700.
6. Kinget R, Kalala W, Vervoot L, Mooter GU. Colonic drug targeting. J Drug Target. 1998;6:129-49.
7. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carr Syst. 1995;12:101-49.
8. Akhgari A, Garekani HA, Sadeghi F, Azimaie M. Statistical optimization of indomethacin pellets coated with pH dependent methacrylic polymers for possible colonic drug delivery. Int J Pharm. 2005;305:22-30.
9. Akhgari A, Sadeghi F, Garekani A. Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets. Int J Pharm. 2006;320:137-42.
10. Krishnaiah YSR, Satyanarayana S, Rama Prasad YV, Narasimha RS. Evaluation of guar gum as a compression coat for drug targeting to colon. Int J Pharm. 1998;171:137-46.
11. Fernández-Hervás MJ, Fell JT. Pectin/chitosan mixtures as coatings for colon-specific drug delivery: An in vitro evaluation. Int J Pharm. 1998;169:115-9.
12. Ji C, Xu H, Wu W. In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS 30D-coated colon-targeted pellets of indomethacin. J Drug Target 2007;15(2):123-31.
13. Wu B, Deng D, Lu Y, Wu W. Biphasic release of indomethacin from HPMC/ pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. Eur J Pharm Biopharm. 2007;67(3):707-14.
14. Sinha VR, Kumria R. Binders for colon specific drug delivery: An in vitro evaluation. Int J Pharm. 2002;249:23-31.
15. Chourasia MK, Jain SK. Design and development of multiparticulate system for targeted drug delivery to colon. Drug Deliv. 2004;11(3):201-7.
16. Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM. Development of polysaccharide-based colon targeted drug delivery systems for the treatment of amoebiasis. Drug Dev Ind Pharm. 2007;33(3):255-64.
17. Mura P, Maestrelli F, Cirri M, González Rodríguez ML, Rabasco Alvarez AM. Development of enteric-coated pectin-based matrix tablets for colonic delivery of theophylline. J Drug Target. 2003;11(6):365-71.
18. Sinha VR, Kumria R. Coating polymers for colon specific drug delivery: A comparative in vitro evaluation. Acta Pharm. 2003;53(1):41-7.
19. Alvarez-Fuentes J, Fernández-Arévalo M, González-Rodríguez ML, Cirri M, Mura P. Development of enteric-coated timed-release matrix tablets for colon targeting. J Drug Target. 2004;12(9-10):607-12.
20. Ibekwe VC, Fadda HM, Parsons GE, Basit AW. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Int J Pharm. 2006;308:52-60.
21. Ibekwe VC, Liu F, Fadda HM, Khela MK, Evans DF, Parsons GE, et al. An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. J Pharm Sci. 2006;95(12):2760-6.
22. Gao C, Huang J, Jiao Y, Shan L, Liu Y, Li Y, et al. In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets. Int J Pharm. 2006;322(1-2):104-12.
23. Li Y, Li HJ, Yang GR, Gu WP, Ma YK, Zhang MH, et al. Colon-specific delivery tablets of sodium 4-aminosalicylic acid. Yao Xue Xue Bao. 2006;41(10):927-32.
24. Cole ET, Scott RA, Connor AL, Wilding IR, Petereit HU, Schminke C, et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm. 2002;231(1):83-95.
25. Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res. 2008;25(8):1828-35.
26. Cheng G, An F, Zou MJ, Sun J, Hao XH, He YX. Time- and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid. World J Gastroenterol. 2004;10(12):1769-74.
27. Brunner M, Lackner E, Exler PS, Fluiter HC, Kletter K, Tschurlovits M, et al. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. Aliment Pharmacol Ther. 2006;23(1):137-44.
28. Ibekwe VC, Khela MK, Evans DF, Basit AW. A new concept in colonic drug targeting: A combined pH-responsive and bacterially-triggered drug delivery technology. Aliment Pharmacol Ther. 2008;28(7):911-6.
29. Ewe K, Schwartz S, Petersen S, Press AG. Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease. Dig Dis Sci. 1999;44:1434-9.
30. Friend DR. Colon-specific drug delivery. Adv Drug Deliv Rev 1991;7:149-99.
31. Rubinstein A. Colonic drug delivery. Drug Discov Today Technol. 2005;2(1):33-7.
32. Asghar LF, Chandran S. Design and evaluation of pH modulated controlled release matrix systems for colon specific delivery of indomethacin. Pharmazie. 2008;63:736-42.
33. Asghar LFA, Chandran S. Design and evaluation of matrices of Eudragit with polycarbophil and carbopol for colon specific delivery. J Drug Target 2008;16:741-57.
34. Chandran S, Kango SS, Asghar LFA. Microspheres with pH modulated release: Design and characterization of formulation variables for colonic delivery. J Microencapsul 2008;22:1-11. doi: 10.1080/ 02652040802424021.
35. J. Varshosaz, N. Tavakoli, F. Kheirolahi. Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride. AAPS PharmSciTech 2006;7(1) Article 24.
36. Andreopoulos AG, Tarantili PA. Xanthan gum as a carrier for controlled release of drugs. J Biomater Appl. 2001;16(1):34-46.
37. Vendruscolo CW, Andreazza IF, Ganter Ferrero JLC, Bresolin TM. Xanthan and galactomannan (from M. scabrella) matrix tablets for oral controlled delivery of theophylline. Int J Pharm. 2005;296(1-2):1-11.
38. Phaechamud T, Ritthidej GC. Sustained-release from layered matrix system comprising chitosan and xanthan gum. Drug Dev Ind Pharm. 2007;33(6):595-605.
39. Sinha VR, Kumria R. Polysaccharide matrices for microbially triggered drug delivery to the colon. Drug Dev Ind Pharm 2004;30(2):143-50.
40. Talukdar MM, Rombaut P, Kinget R. The release mechanism of an oral controlled-release delivery system for indomethacin. Pharm Dev Technol. 1998;3(1):1-6.
41. Yeole PG, Galgatte UC, Babla IB, Nakhat PD. Design and evaluation of xanthan gum-based sustained release matrix tablets of diclofenac sodium. Indian J Pharm Sci 2006;68(2):185-9.
42. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983;15:25-35.
43. Ritger PL, Peppas NA. A simple equation for the description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release. 1987;5:23-36.
44. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20:64-74.
45. Li SP, Feld KM, Kowarski CR. Preparation and evaluation of Eudragit acrylic resin for controlled drug release of pseudoephedrine hydrochloride. Drug Dev Ind Pharm. 1991;17:1655-83.
46. Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, et al. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev Ind Pharm. 2004;30(3):303-17.
47. Ammar HO, Khalil RM. Preparation and evaluation of sustained-release solid dispersions of drugs with Eudragit polymers. Drug Dev Ind Pharm. 1997;23(11):1043-54.
48. Kislalioglu MS, Khan MA, Blount C, Goettch RW, Bolton S. Physical characterization and dissolution properties of ibuprofen: Eudragit coprecipitates. J Pharm Sci 1991;80:799-804.
49. Fadda HM, Basit AW. Dissolution of pH responsive formulations in media resembling intestinal fluids: Bicarbonate vs. phosphate buffers. J Drug Deliv Sci Technol 2005;15:273-9.
50. Sheu MT, Chou HL, Kao CC, Liu CH, Sokoloski TD. Dissolution of diclofenac sodium from matrix tablets. Int J Pharm. 1992;85:57-63.
51. Saha RN, Sajeev C, Sahoo J. A comparative study of controlled release matrix tablets of diclofenac sodium, ciprofloxacin hydrochloride and theophylline. Drug Deliv. 2001;8(3):149-54.
52. Chan WA, Boswell CD, Zhang Z. Comparison of the release profiles of a water soluble drug carried by Eudragit coated capsules in different in vitro dissolution liquids. Powder Technol. 2001;119:26-32.
53. Akiyama Y, Yoshioka M, Horibe H, Hirai S, Kitamori N, Toguchi H. pH-independent controlled-release microspheres using polyglycerol ester-fatty acids. J Pharm Sci. 1994;83:1600-7.
54. Follonier N, Doelker E. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms. STP Pharma Sci. 1992;2:141-55.
55. Hinton JM, Lennard-Jonnes JE, Young AC. A new method for studying gut transit times using radioopaque markers. Gut. 1969;10:842.
56. McConell EL, Basit AW, Murdan S. Measurement of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in vivo experiments. J Pharm Pharmacol. 2008;60:63-70.